Sheet	1	of	1
311000	1	OI	1

Substitute Form TO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 07039-235001

Application No. 09/824,924

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant Christopher Eckman et al.

Filing Date

Group Art Unit

(37 CFR §1.98(b))

April 3, 2001

U.S. Patent Documents Desig. Examiner Document Publication Number Initial ID Date Patentee Class Subclass OC AA5,736,376 04/07/98 Yanagisawa AB ACAD ΑE AF AG AH ΑI AJ AK

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans	slation
OC	AL	WO 00/65025	11/02/00	PCT	0.033	Oubclass	Yes	No
	AM							
	AN				+			
	AO				1			
	AP			_				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	The state of Fublication
Initial	ID	Document
oc	AQ	Brown et al., "Functional Significance of the Isoforms of Endothelin-Converting Enzyme-1," <u>J.</u> <u>Cardiovasc. Pharmacol.</u> , 2000, 36(Suppl. 1):S26-S27
00	AR	Eckman et al., "Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme," J. Biol. Chem., 2001, 276(27):24540-24548
	AS	7, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10
	AT	

Examiner Signature	Date Considered 4
alleyson	05/14/03
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and set esseit
next communication to applicant.	the combination and not considered. Include copy of this form with